Health Industry Manufacturers Association

C. H. Swanson, Statementfor the Health Industry Manufacturers Association, before the House Government Operations Subcommittee in Information, Justice, Transportation, and Agriculture, Washington, D.C., Oct. 5, 1994. 

The microbiological studies above are conducted to establish the appropriate dose level to be used to sterilize each specific product or commodity to an acceptable level of statistical nonsterility. These studies should be conducted following qualification of the irradiation facility. The Health Industry Manufacturers Associ-aton (HIMA) [39] has suggested major items to be included in the qualification phase of the validation scheme for radiation sterilization installation. 

Health Industry Manufacturers Association. Medical Device Sterilization Monographs, Sterilization Cycle Development, report no. 78-4.2 (1978). 

Health Industry Manufacturers Association (HIMA), Microbiological evaluation of filters for sterihzing hquids, HIMA Document No.3, Vol. 4, 34 pp., 1982. 

A. A. Rosenblatt and J. E. Knapp, Health Industry Manufacturer s Association (HTMAJ Conference Proceedings, 1988, Washington, D.C., pp. 47—50. 

Health Industry Manufacturer s Association (devices) Health Insurance Portability and Accountability Act Indian Health Service Human immunodeficiency vims HIV-positive HIV-infected Human immunodeficiency vims type 1 Health Maintenance Organization... 

During the dozen or so years in which I have been either Chairman or President of our Health Food Manufacturers Association I have tried whole-heartedly to increase the credibility of the health food industry and to improve its relationships with orthodox scientists. The result of this, combined with ever-increasing voluntary controls on advertising and product quality, has in many cases led to a close and productive relationship. 

The chapters in Part III therefore tease out experiences of some of the key aspects of health-industry interactions in more detail and identify some important policy issues to be tackled. All these issues are framed by political economy considerations of the ethics, interests and institutions involved. They include the highly contentious matters of price controls and standard setting for pharmaceutical products, plus examination of sources and problems of financing, the scope for innovative procurement processes that can reflect health system values while providing incentives for industrial investment, and the contested but important role of industrial manufacturers associations and political lobbying. 

American Council on Science and Health (ACSH), 278 American Crop Protection Association (ACPA), 267, 278 American Cyanamid Agricultural Products Division, See BASF Agricultural Products Group (US), 216 American Fiber Manufacturers Association, hic. (AFMA), 268 American Hydrogen Association (AHA), 268 American Industrial Hygiene Association (AIHA), 278 American Institute of Chemical Engineers (AICHE), 268 American Institute of Chemists, The (AIC), 268 American Methanol Institute (AMI), 268 American Oil Chemists Society (AOCS), 268 American Ordnance LLC, 216 American Pacific Corporation (AMPAC), 216 American Peptide Society (APS), 268... 

Now, what can EPA or anyone else do about this elusive but real problem A start has already been made via a data quality workshop which was initiated by the CMA (Chemical Manufacturers Association) and co-sponsored by EPA, NBS (National Bureau of Standards) and NAS (National Academy of Sciences). This resulted in a group of about 40 experienced participants from government, industry and academia reviewing criteria for data quality in four areas of information relating to properties, health and environmental effects. From this beginning, we eventually hope to see the contents of data-bases or data files identified as to the level of reliability of extracted information. The user will then at least have the ability to judge the value of the information he received. 

The International Federation of Pharmaceutical Manufacturers Associations (IFPMA). IFPMA represents the worldwide research-based pharmaceutical industry and facilitates the development of position statements on policy issues. It serves as a bridge between industry, the WHO, and other international health agencies. It also serves at the ICH secretariat. 

The pharmaceutical industry was very pleased with the actions of the ustr, but decided to pursue the matter further. In February 1998, the consortium of 40 drug companies, led by the Pharmaceutical Manufacturers Association of South Africa, filed a suit. Its key legal claim was that the statute, the Medicines Amendment Act of 1997, was in violation of South African obligations under trips. It was also claimed that the statute was unconstitutional because it gave sweeping power to South Africa s health minister to override the country s patent laws (Kongolo, 2001). For its part, the South African government promised to defend the Medicines Act, which could not be implemented because of the lawsuit. 

The International Conferences was jointly supported and organized by the Commission of the European Communities (CEC), the US Food and Drug Administration (FDA), the Japanese Ministry of Health and Welfare (MHW), together with the pharmaceutical industry, as represented by the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), the European Federation of Pharmaceutical Industry Associations (EFPIA), the US Pharmaceutical Manufacturers Association (PMA) and the Japanese Pharmaceutical Manufacturers Association (PMA). 

---